Full Text View
Tabular View
No Study Results Posted
Related Studies
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)
This study has been terminated.
( Recruitment was too difficult )
Study NCT00211380   Information provided by Louisiana State University - Shreveport
First Received: September 13, 2005   Last Updated: February 6, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Schizoaffective Disorder
Additional conditions recognized in this trial
Disease
Psychotic Disorders
More general conditions related to this trial
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
aripiprazole
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Louisiana State University - Shreveport
SAM Technology &The San Francisco Brain Research Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services